Solomon J Lubinga

4PUBLICATIONS
10CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jul 06, 2026
Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis.

|Mar 28, 2025
Real-World Molecular Testing Rates and Patterns in Patients With Primary Advanced or Recurrent Endometrial Cancer in the United States.

Yilin Chen, Solomon J Lubinga, Troy Williams

|Sep 10, 2024
Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspective.

Solomon J Lubinga, Lydia Walder, Mark Burton

|Jun 06, 2022
Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.

Malin Berling, Mohammad A Chaudhary, Yong Yuan

Pageof 1

Frequent Collaborators

2 joint publications

Yilin Chen

2 joint publications

Josh J Carlson

2 joint publications

Scott Ramsey

1 joint publications

Mohammad A Chaudhary